Price T Rowe Associates Inc Tarsus Pharmaceuticals, Inc. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 460,773 shares of TARS stock, worth $21.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
460,773
Previous 239,315
92.54%
Holding current value
$21.7 Million
Previous $7.87 Million
224.11%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding TARS
# of Institutions
201Shares Held
40.5MCall Options Held
72.7KPut Options Held
313K-
Black Rock Inc. New York, NY3.27MShares$154 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY3.24MShares$152 Million2.92% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.53MShares$119 Million5.35% of portfolio
-
Jennison Associates LLC2.5MShares$118 Million0.09% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$106 Million9.38% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.26B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...